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Abstract
Background: The gene encoding carboxyl-terminal PDZ ligand of neuronal nitric oxide synthase (NOS1AP) is
located on chromosome 1q23.3, a candidate region for schizophrenia, autism spectrum disorders (ASD) and
obsessive-compulsive disorder (OCD). Previous genetic and functional studies explored the role of NOS1AP in these
psychiatric conditions, but only a limited number explored the sequence variability of NOS1AP.
Methods: We analyzed the coding sequence of NOS1AP in a large population (n = 280), including patients with
schizophrenia (n = 72), ASD (n = 81) or OCD (n = 34), and in healthy volunteers controlled for the absence of
personal or familial history of psychiatric disorders (n = 93).
Results: Two non-synonymous variations, V37I and D423N were identified in two families, one with two siblings
with OCD and the other with two brothers with ASD. These rare variations apparently segregate with the presence
of psychiatric conditions.
Conclusions: Coding variations of NOS1AP are relatively rare in patients and controls. Nevertheless, we report the
first non-synonymous variations within the human NOS1AP gene that warrant further genetic and functional
investigations to ascertain their roles in the susceptibility to psychiatric disorders.
Background
The current concepts adopted by DSM-IV and ICD-10
that define a psychiatric disorder as a single entity may
be misleading and hamper the identification of suscept-
ibility genes. Some disorders classically considered as
separate conditions could be envisaged as being the phe-
notypic extremes of a continuum caused by an overlap-
ping set of genes. Indeed, the same region on
chromosome 1q23.3 was detected in whole genome scans
for separate psychiatric disorders and could therefore
contain one shared susceptibility gene for these condi-
tions. For schizophrenia, several linkage studies detected
a significant linkage at 1q23.3 [1-6]. The same region was
detected in two linkage studies in autism spectrum disor-
ders (ASD). Buxbaum et al., [7] reported an association
between patients with autism and obsessive-compulsive
behaviors (OCD), and D1S1677 (p value = 0.003 under
multipoint nonparametric analyses). These results were
replicated by Ylisaukko-oja et al., [8] who found a signifi-
cant linkage between patients with Asperger syndrome,
known to have frequent OC symptoms [9], and 1q23.3
(D1S484, LOD score = 3.58 under dominant model). In
OCD patients a linkage at chromosome 1q23.3 was
observed in the early-onset group (age at onset <18
years) [10]. Non parametric multipoint linkage analysis
produced a maximum LOD score of 2.94 at D1S1679
with an empirical p value equal at 0.001 after
permutations.
Several genes located in region 1q23.3 have been stu-
died, e.g. the regulator of G-protein signalling 4 gene
[11-14], the myelin protein zero like 1 gene [15], the
UHMK1 gene [16], encoding for a serine/threonine pro-
tein kinase, and the carboxyl-terminal PDZ ligand of
neural nitric synthase (NOS1AP) gene. Among these
genes, NOS1AP remains the most promising candidate.
Brzustowicz et al., [17] analyzed 14 microsatellites and
15 single nucleotide polymorphisms (SNPs) between
D1S1653 and D1S1679, and found a significant* Correspondence: richard.delorme@rdb.aphp.fr
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association between NOS1AP and SCZ. These results
were reproduced in three independent samples of
patients [18-20]. NOS1AP is in adaptor protein, which
binds to neuronal nitric oxyde synthase, eliciting S-
nitrosylation and activation of Dextras 1, which regulate
NMDA receptor-mediated glutamate neurotransmission
[21]. Using quantitative real time polymerase chain reac-
tion, Xu et al., [22] reported an increased of the
NOS1AP short isoform mRNA in the dorso-prefrontal
cortex of schizophrenic patients. The over expression
this short isoform mRNA could disrupt NMDA receptor
function [23] and increase the risk of a psychiatric con-
dition such as SCZ, ASD or OCD. More recently, Wrat-
ten et al., [24] reported that a risk allele, located in
intron 2 and associated with schizophrenia, could
enhance transcription factor binding and increase gene
expression. Together, these findings make NOS1AP as a
compelling candidate for several psychiatric disorders.
However, no coding mutation in NOS1AP has been
reported [17] and the positive association only concerns
SNPs that have no established functional role. The aim
of this study was to explore the expression pattern of
NOS1AP in human tissues and its sequence variability
in a large population of subjects (n = 280), including
patients with schizophrenia (n = 72), ASD (n = 81) or
OCD (n = 34), and in healthy volunteers controlled for
the absence of personal or familial history of psychiatric
disorders (n = 93).
Methods
Patients
Schizophrenic (46 males, 26 females) and OCD (21
males, 13 females), fulfilling the DSM-IV criteria for
their disorders, were recruited in Paris (Department of
Adult Psychiatry, H. Mondor and A. Chenevier Hospi-
tals, Créteil, and Department of Child and Adolescent
Psychiatry, R Debré Hospital, France). Lifetime psychia-
tric evaluation was carried out during a direct interview
by trained psychiatrists using the Diagnostic Interview
for Genetic Studies (DIGS) [25] and the Kiddie-Schedule
of Affective Disorders and Schizophrenia - epidemiolo-
gic version [26] for OCD probands aged under 18 years.
Probands with ASD (72 males, 9 females; 46 trios, 35
multiplex families) were recruited by the Paris Autism
Research International Sib-pair (PARIS) study. Patients
with autism or Asperger’s syndrome fulfilled the DSM-
IV criteria for autistic disorder and the Autism Diagnos-
tic Interview Revised algorithm for ICD-10 childhood
autism and the Autism Diagnostic Interview-Revised
[27] criteria for childhood autism. Subjects were
included only after a thorough clinical and medical
work-up comprising a full medical and family history,
physical and neuropsychological examination, standard
karyotyping and fragile-X testing, blood and urine
analyses for metabolic screening. Healthy controls of
European descent (n = 93) were recruited among blood
donors at the Pitié-Salpétrière Hospital in Paris, France
(49 males, 44 females). All controls were included after
being interviewed with the DIGS and with the Family
Interview for Genetic Studies [28] to confirm the
absence of both personal and familial history of psychia-
tric disorders.
The local Research Ethics Boards reviewed and
approved the study. Written informed consent was
obtained from all probands and controls. If the proband
was under 18 years old, the proband’s consent and writ-
ten parental consent were obtained.
Gene characterization
The genomic structure of NOS1AP was obtained from
http://genome.ucsc.edu/. Exon-intron boundaries were
identified and primers designed to cover the regulatory
splice site regions and the exons using the previous
Web site. NOS1AP covers a genomic region of 298 Kb
and comprises 10 exons. As reported by Xu et al., [19],
the long isoform is composed of exons 1 to 10 and
encodes a protein of 75 kDa. The short isoform is com-
posed of exons 9 and 10, and encodes a protein of
30 kDa. Both proteins contain a PDZ domain.
Expression of NOS1AP long and short isoforms in human
tissues
One microgram of total RNA from different tissues and
specifically from regions of the human brain was reverse
transcribed using the Gene Amp RNA PCR kit (Perkin-
Elmer Corp., Norwalk, CT) and primers located in
exons 1-7, 6-9 and 8-10 (forward -reverse) for the long
isoform and in the 3’UTR-exon10 for the short isoform
[22]. The ages of the two males and the two females
studied were 74, 42, 55, and 36 years-old, with a post-
mortem delay of 10, 21, 24, and 2 h, respectively.
Normal control human brains were obtained at autopsy
under guidelines approved by the ethics committee
Mutation screening in psychiatric patients
The mutation screening was conducted in two steps.
First, the exonic sequences of NOS1AP were screened
for genetic variants by direct sequencing with the
BigDye kit v3.0 (Applied Biosystems) according to the
manufacturer’s instructions in a sample of schizophrenic
patients (n = 72), ASD patients (n = 81) and healthy
volunteers (n = 93). The exonic sequence and the adja-
cent intronic sequences were considered first as most
likely to harbour functionally important variants. Pri-
mers were designed using Amplify V3.1 software http://
engels.genetics.wisc.edu/amplify/ and are available on
request. Then, the rare variants identified were screened
by direct sequencing in a additionnal sample containing
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224 patients with ASD and 225 patients with schizo-
phrenia. Patients included in this second step fulfilled
the same criteria as patients enrolled in the first steps of
the study and described previously.
Association study in schizophrenic and ASD patients
The association study was conduct using 11 SNPs with a
minor allele frequency higher than 0.05 and identified
by direct sequencing in the schizophrenic and ASD
patients (table 1). The program HaploView (v3.32) was
used to test for concordance with Hardy-Weinberg
equilibrium (HWE), calculate D’ between SNP pairs and
identify linkage disequilibrium (LD) blocks, which were
defined with confidence intervals [29]. The P values for
each marker and haplotype were adjusted from permu-
tation test with 10,000 simulations if significance was
under 0.01. Comparison of genotype frequencies
between cases and controls was performed with
Table 1 Allele and genotype frequencies of frequent polymorphisms in NOS1AP*
Polymorphisms# Location Number of alleles (frequency) Number of Genotype (frequency)
Allele 1 Allele 2 P (df = 1) 11 12 22 P (df = 2)
rs10918776 Intron 2 G C
SCZ 100 (0.77) 32 (0.23) 0.46 42 22 5 0.57§
ASD 117 (0.72) 45 (0.28) 0.06 39 37 4 0.06§
Controls 142 (0.80) 34 (0.20) 57 28 3
rs10800405 Intron 3 C G
SCZ 91 (0.76) 31 (024) 0.92 37 25 3 0.98§
ASD 102 (0.74) 36 (0.26) 0.63 34 33 1 0.60§
Controls 113 (0.77) 35 (0.23) 43 29 3
rs347306 and rs347307 Intron 5 C and T T and C
SCZ 74 (0.56) 60 (0.44) 0.19 20 38 12 0.23
ASD 82 (0.52) 76 (0.48) 0.98 17 41 20 0.46
Controls 87 (0.52) 81 (0.48) 15 54 18
rs3751285 Intron 6 A G
SCZ 68 (0.77) 20 (0.33) 0.35 28 12 4 0.32§
ASD 97 (0.71) 39 (0.29) 0.96 34 27 6 0.97
Controls 106 (0.72) 42 (0.28) 39 31 6
rs3751284 Exon 6 C T
SCZ 58 (0.66) 30 (0.34) 0.35 20 18 6 0.45
ASD 75 (0.55) 61 (0.45) 0.32 20 34 13 0.69
Controls 88 (0.60) 60 (0.40) 26 39 11
rs905721 Intron 8 C T
SCZ 96 (0.70) 42 (0.30) 0.10 33 30 6 0.22
All SCZ 353 (0.62) 213 (0.38) 0.92 114 125 44 0.86
ASD 104 (0.66) 54 (0.34) 0.33 31 41 6 0.02
All ASD 360 (0.64) 198 (0.36) 0.41 115 130 34 0.27
Controls 98 (0.65) 52 (0.35) 37 24 14
All controls 309 (0.62) 189 (0.38) 102 105 42
rs348624 and rs1964052 Exon 9 and intron 9 C and C T and T
SCZ 121 (0.89) 15 (0.11) 0.48 54 13 1 0.49§
All SCZ 500 (0.87) 74 (0.13) 0.34 218 63 6 0.50
ASD 132 (0.85) 24 (0.15) 0.07 55 18 3 0.07§
All ASD 472 (0.86) 74 (0.14) 0.22 206 60 7 0.39
Controls 137 (0.91) 13 (0.09) 62 13 0
All controls 283 (0.89) 34 (0.11) 128 29 2
rs164146 and rs164147 Exon 10 G and C C and A
SCZ 104 (0.83) 22 (0.17) 0.71 43 18 2 0.73§
ASD 133 (0.84) 25 (0.16) 0.99 56 20 2 0.91§
Controls 128 (0.84) 24 (0.16) 57 23 1
*Polymorphisms included have a minor allele frequency above 0.05. # Markers are listed from centromere au telomere. § Fischer exact Test. Significant P values
(<0.05) are in bold. Abbreviations: ASD: autism spectrum disorders, SCZ: schizophrenia.
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chi-square test. The association study was conducted in
two steps: first, all the schizophrenic patients (n = 72)
and all the ASD patients (n = 81) were compared to the
healthy volunteers (n = 93) to detect a potential associa-
tion. Second, we included additional schizophrenic
patients (n = 224), ASD patients (n = 225) and controls
(n = 193) to increase the power of detecting an associa-
tion with the SNP rs348624 (R334R) located in exon 9.
This SNP was previously reported to be associated with
schizophrenia [19]. For the additional subjects, geno-
types were determined by TaqMan assay for allelic dis-
crimination using the ABI Prism® 7000 Sequence
Detection System (Applied Biosystems, Foster City, CA).
Schizophrenic and ASD patients were the same as those
included in the second step of the mutation screening.
Results
Expression of the NOS1AP long and short isoforms in the
human tissues
In order to study the expression pattern of the NOS1AP
long and short isoforms in human tissues, we performed
reverse transcriptase - polymerase chain reactions (RT-
PCR) on RNA isolated from different tissues and brains
regions (figure 1). Brain samples were obtained from
four control individuals. These RT-PCR results are non
quantitative and should be taken with care. However,
NOS1AP long and short isoforms were not restricted to
the brain, but were also detected in testis, prostate,
small intestine, blood leukocyte, heart, placenta, lung,
kidney and pancreas. In brain, the two isoforms of
NOS1AP were also not restricted to a specific brain
region (figure 1) and displayed high inter-individual
differences.
Mutation screening of NOS1AP in individuals with
psychiatric disorders
All the exons of NOS1AP were directly sequenced in a
large subset of subjects (n = 280), including patients
with schizophrenia (n = 72), ASD (n = 81) and OCD
(n = 34), and in healthy volunteers (n = 93). Only two
non-synonymous variations, V37I and D423N were
identified (figure 2). V37I was detected in one female
patient with OCD. The mutation was also present in
her affected brother with OCD and was transmitted by
the mother suffering from panic attack (figure 2). We
were unable to detect this variation in the extended
Figure 1 Expression analysis of NOS1AP short and long isoforms in normal control human tissues. One microgram of total RNA from
different tissues and specifically from regions of the human brain was reverse transcribed using the Gene Amp RNA PCR kit (Perkin-Elmer Corp.,
Norwalk, CT) and primers located in exons 1-7, 6-9 and 8-10 (forward -reverse). The ages of the two males and the two females studied were 74,
42, 55, and 36 years-old, with a post-mortem delay of 10, 21, 24, and 2 h, respectively. f: frontal cortex, tc: temporal cortex, o: occipital cortex, h:
hippocampus, t: thalamus; c: cerebellum. Normal control human brains were obtained at autopsy under guidelines approved by the ethics
committee.
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sample of patients with ASD (n = 224) or schizophrenia
(n = 225). This rare variant was located in the phospho-
tyrosin-binding domain that is conserved among mam-
mals, but not in Xenopus and Zebra fish, the latter
having a valine to an isoleucine substitution.
The second non-synonymous variation, D423N, was
detected in three brothers (figure 2), two affected with
ASD and mild mental retardation, and one with social
phobia. Two additional brothers with language delay
and no autistic symptoms do not carry the mutation.
The mutation was transmitted by the father who has a
schizotypical personality and a history of language delay
during childhood (figure 2). The variation D423N was
absent from the extended sample of patients with ASD
(n = 224), schizophrenia (n = 225) and an additional set
of 95 controls from North African descent since pro-
band had North African ancestors. D423 is highly con-
served among species (figure 2) and is adjacent to the
PDZ domain of the short and long isoform of the pro-
tein. The variation D423N changes a negatively charged
amino acid into a polar uncharged residue. In silico, the
variation D423N is predicted to alter the protein
stability (delta G of -1.16) and function (SIFT program:
score <0.001).
Association study in schizophrenic and ASD patients
In order to test if frequent polymorphisms within NOS1AP
were associated with susceptibility to psychiatric disorders,
we assessed the frequency of 11 SNPs in patients and con-
trols. Distributions of allelic frequencies of all markers
were in Hardy Weinberg Equilibrium in cases and controls
(p > 0.10). The rs347306 and rs347307 located in intron 5
are in strong LD whatever the population considered. Also,
rs348624, rs1964052, rs164146 and rs164147 were in the
same LD block located in the 3’region of NOS1AP (figure
3). We could not detect any significant allelic frequency
difference between SCZ and controls or between ASD and
controls (table 1). Haplotype analyses defined with confi-
dence intervals did not find any significantly association
either (table 2). In order to test the previously observed
association between SCZ and SNP rs348624 (R334R)
located in exon 9, an additional sample of SCZ (n = 224),
ASD patients (n = 225) and controls (n = 193) were geno-
typed. However, no allelic association was observed.
Figure 2 Familial segregation and conservation among species of V37I and D423N located in NOS1AP gene.
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Figure 3 Schematic representation of NOS1AP with location of frequent single nucleotide polymorphisms and Haploview-generated
linkage disequilibrium map of the NOS1AP. Region of high LD (D’ = 1) are shown in bright red. Only ASD, OCD, schizophrenic and control
subjets patients are shown in the LD diagram. The numbers in the squares are D prime values (×100).
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Discussion
The lack of association between frequent NOS1AP poly-
morphism and susceptibility to SCZ are in accordance
with those obtained in a Caucasian population [30], but
contrast with a case control study conducted in a Chi-
nese population, reporting an association between SCZ
and rs348624. These contradictory results could be due
to a difference in allelic frequency between populations.
Indeed, the major allele frequency for rs348624 in Chi-
nese SCZ patients (0.87) is similar in our patients (SCZ
0.87; ASD 0.86), but the two control populations differ
in allelic frequencies (Chinese controls: 0.82; French
controls: 0.89). In addition, the association was only sug-
gestive since the same group did not replicate their
results when using a family-based approach [31].
The lack of association between frequent SNPs and the
disorder does not exclude NOS1AP as a susceptibility
gene to psychiatric conditions. Indeed, a larger sample
size might detect an association between SCZ and fre-
quent NOS1AP polymorphism. In addition, private muta-
tions altering the function of NOS1AP may also
contribute to the disorder in a subset of patients. Our
mutation screening (280 subjects, including patients with
SCZ, ASD, OCD, and controls) showed that variations
altering the protein sequence of NOS1AP are rare - at
least among individuals of European descent. Neverthe-
less, two changes V37I and D423N were identified in one
family with OCD and in one family with ASD, respec-
tively. In public databases three non synonymous varia-
tions for NOS1AP, namely: rs41405649, rs4127196,
rs34398505 are reported http://www.ncbi.nlm.nih.gov.
However, their genotype has not been validated by an
independent method and their frequency has not been
reported, except for rs34398505 (0.061). The single indi-
vidual carrying this non synonymous rare variant
(NA14649) is a female from African-American ancestor.
The variation 37I reported in the OCD family, was pre-
sent in two affected siblings and in the mother. The
mother was directly interviewed, and she suffers from
sever panic disorder. In the ASD family, the variation
423N segregated with the presence of psychiatric condi-
tions related the broad autism phenotype [32,33]. The
variant was present in the two affected male siblings, in
the brother suffering from a social phobia and trans-
mitted by the father who had a schizotypical personality.
The two unaffected brothers do not carry the mutation
and have no autistic symptoms. If NOS1AP plays a role
in the susceptibility to ASD, it may represent only one of
the contributing factors required for the full phenotypic
trait of ASD. The conservation of 37I and 423N observed
among species suggests that substitution could influence
protein function. The mutation V37I only concerns the
long NOS1AP isoform, whereas D423N is present in both
the short and the long isoform of NOS1AP. Specifically,
D423N mutation seems to decrease the protein stability
as predicted by the Prediction of Protein Stability
Changes upon Mutations Program http://www.ics.uci.
edu/~baldig/mutation.html with a delta G of -1.16. Also,
similar results were obtained using the SIFT program.
The D to N substitution in position 423 is predicted to
affect protein function http://sift.jcvi.org/ with a score
under 0.001. At this stage, we lack information on the
specific impact of these variants on NOS1AP function to
decipher whether these mutations contribute or not to
the disorder. Thus, the functional analyses of NOS1AP
variants as well as the identification of the genetic/envir-
onmental factors, that modulate the expression of
NOS1AP in the human brain, are needed to reinforce the
potential implication of this gene in the susceptibility to
OCD or ASD.
In our four controls individuals, expression of both
NOSAP1 isoforms displayed high inter-individual differ-
ences whatever the explored brain regions. This inter-
individual variability in the expression of NOS1AP
might contribute to the increased of the short isoform
mRNA in the dorso-prefrontal cortex of patients with
SCZ [22].
Conclusions
As reported by Brzustowicz et al., for SCZ [17], varia-
tions within the coding sequence of NOS1AP are rare
and therefore cannot be considered as susceptibility fac-
tors to ASD, OCD and SCZ. However, we cannot
exclude that for a very small subset of patients with
Table 2 Estimated haplotype frequencies in NOS1AP
Haplotype block Frequency (%) P values






CT 0.55 0.48 0.48 0.23 0.98
TC 0.45 0.52 0.52 0.23 0.98
2 (rs3751285 -
rs3751285)
AG 0.56 0.46 0.59 0.28 0.45
GT 0.23 0.28 0.28 0.40 0.96
AT 0.11 0.17 0.13 0.74 0.33
3 (rs348624 -
rs1964052)
CC 0.89 0.85 0.91 0.50 0.07*
TT 0.11 0.15 0.08 0.50 0.07*
4 (rs164146 -
rs164147)
GC 0.83 0.84 0.84 0.71 0.99
CA 0.18 0.16 0.16 0.71 0.99
* P = 0.53 when 10000 permutations where simulated. Significant P values
(<0.05) are in bold. Abbreviations: ASD: autism spectrum disorders, SCZ:
schizophrenia.
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OCD and ASD, NOS1AP may contribute to the dis-
order. Further genetic and functional studies are war-
ranted to understand the role of NOS1AP in the
susceptibility to psychiatric disorders.
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